Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.
暂无分享，去创建一个
D. Chakrabarti | A. Shaw | E. Felip | S. Ramalingam | B. Solomon | Patrick Ezeh | Sang-We Kim | Ji-Youn Han | Se-Hoon Lee | M. Nishio | B. Hughes | T. Seto | M. Boyer | T. Hida | Andrew Chang | T. Bauer | L. Fumagalli | Jing Wang | E. C. Costa